According to a new market research report published by Global Market Estimates, the Global Neuroendocrine Tumor Treatment Market is projected to grow from USD 1.8 billion in 2021 to USD 2.1 billion by 2026 at a CAGR value of 5.7% from 2021 to 2026. High prevalence of neuropsychiatric malignancy, awareness regarding early cancer diagnosis, and an increasing number of government initiatives, the neuroendocrine tumor therapy market is expected to rise rapidly.
Browse 151 Market Data Tables and 111 Figures spread through 181 Pages and in-depth TOC on “Global Neuroendocrine Tumor Treatment Market - Forecast to 2026”
https://www.globalmarketestimates.com/market-report/neuroendocrine-tumor-treatment-market-3631
By Product (Somatostatin Analog (SSAs), Targeted Therapy, Chemotherapy and Others), By Indication (Lungs, Pancreas, Gastrointestinal, Others), By Site (Lungs, Pancreas, Colon, Small Intestine, Others), By Route of administration (Oral, Parenteral), By End-User (Hospitals, Specialty Clinics, Radiation Centers, Home Healthcare and Others), Competitive Landscape, Company Market Share Analysis, and Competitor Analysis
Key Market Insights
- As per the product outlook, somatostatin analog (SSAs) segment is expected to have the largest share
- The small intestine segment is expected to have the largest share in the market as per site outlook, due to the fact that NETs are more likely to form in the gastrointestinal system
- The oral segment as per route of administration outlook, is expected to have the largest share in the market from 2021 to 2026
- During the forecast period, the market for hospitals segment is expected to have the largest share as per end-user outlook
- Pfizer Inc, Novartis AG, Ispen SA, Advanced Accelerator Applications, Inc., F. Hoffmann-La Roche Ltd., Amgen, Inc., Tarveda Therapeutics, Progenics Pharmaceuticals, Inc., Hutchison Medipharma Limited, are among the key players in the neuroendocrine tumor treatment market.
Browse the Report @ https://www.globalmarketestimates.com/market-report/neuroendocrine-tumor-treatment-market-3631
Product Outlook (Revenue, USD Billion, 2021-2026)
- Somatostatin Analog (SSAs)
- Targeted Therapy
- Chemotherapy
- Others
Indication Outlook (Revenue, USD Billion, 2021-2026)
- Lungs
- Pancreas
- Gastrointestinal
- Others
Route of Administration Outlook (Revenue, USD Billion, 2021-2026)
- Oral
- Parenteral
Site Outlook (Revenue, USD Billion, 2021-2026)
- Lungs
- Pancreas
- Colon
- Small Intestine
- Others
End-User Outlook (Revenue, USD Billion, 2021-2026)
- Hospitals
- Specialty Clinics
- Radiation Centers
- Home Healthcare
- Others
Regional Outlook (Revenue, USD Billion, 2021-2026)
North America
- The U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Rest of APAC
Central & South America
- Brazil
- Argentina
- Rest of CSA
Middle East & Africa
- Saudi Arabia
- UAE
- Rest of MEA
Contact: Yash Jain
Email address: yash.jain@globalmarketestimates.com
Phone Number: +16026667238
Website: Global Market Estimates
Check our Latest Blogs: https://www.globalmarketestimates.com/blog-posts.php